152 related articles for article (PubMed ID: 18520813)
1. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Wagner M; Besse B; Balleyguier C; Soria JC
J Thorac Oncol; 2008 Jun; 3(6):677-9. PubMed ID: 18520813
[No Abstract] [Full Text] [Related]
2. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
[TBL] [Abstract][Full Text] [Related]
3. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Wu SG; Shih JY; Yu CJ; Yang PC
J Thorac Oncol; 2008 Apr; 3(4):451-2. PubMed ID: 18379370
[No Abstract] [Full Text] [Related]
5. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Clarke JL; Pao W; Wu N; Miller VA; Lassman AB
J Neurooncol; 2010 Sep; 99(2):283-6. PubMed ID: 20146086
[TBL] [Abstract][Full Text] [Related]
6. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
8. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
[No Abstract] [Full Text] [Related]
9. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
[No Abstract] [Full Text] [Related]
10. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
11. Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Giovannini M; Belli C; Villa E; Gregorc V
J Thorac Oncol; 2008 Jun; 3(6):684-5. PubMed ID: 18520816
[No Abstract] [Full Text] [Related]
12. Drug interaction between complementary herbal medicines and gefitinib.
Hwang SW; Han HS; Lim KY; Han JY
J Thorac Oncol; 2008 Aug; 3(8):942-3. PubMed ID: 18670318
[No Abstract] [Full Text] [Related]
13. An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Ghosn M; Assi T; El Rassy E; Moussa T; Kattan J
Bull Cancer; 2017 Apr; 104(4):385-387. PubMed ID: 28131317
[No Abstract] [Full Text] [Related]
14. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
[No Abstract] [Full Text] [Related]
15. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Dhruva N; Socinski MA
J Clin Oncol; 2009 Aug; 27(22):e31-2. PubMed ID: 19487379
[No Abstract] [Full Text] [Related]
16. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Hata A; Kaji R; Fujita S; Katakami N
J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
[No Abstract] [Full Text] [Related]
17. High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
Kuiper JL; Heideman DA; Thunnissen E; van Wijk AW; Postmus PE; Smit EF
Eur J Cancer; 2014 May; 50(7):1399-401. PubMed ID: 24582911
[No Abstract] [Full Text] [Related]
18. Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
Garfield D; Kashef G
Lung Cancer; 2006 Mar; 51(3):389-90. PubMed ID: 16359750
[No Abstract] [Full Text] [Related]
19. An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Chan AW; Tong JH; Lo SH; To KF
J Thorac Oncol; 2013 Dec; 8(12):e107-8. PubMed ID: 24389445
[No Abstract] [Full Text] [Related]
20. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Vasile E; Tibaldi C; Chella A; Falcone A
J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
